03:03 PM EDT, 08/05/2025 (MT Newswires) -- Tevogen Bio ( TVGN ) said Tuesday its artificial intelligence project, Tevogen.AI, is expanding its collaboration with Microsoft ( MSFT ) and Databricks to develop the beta version of its PredicTcell model, focusing on oncology.

Tevogen.AI started curating an oncology-focused dataset powered by the Databricks Data Intelligence Platform. The beta version of the PredicTcell model will incorporate oncology targets to refine the accuracy of the model and speed up cancer immunotherapy development, according to a statement.

This phase of development follows Tevogen.AI's recently published international patent application, which outlines novel machine learning systems for forecasting immunologically active peptides, the company said.

Tevogen shares were up 20% in recent trading.

Price: 1.22, Change: +0.22, Percent Change: +22.41